Back to Library

Differential Responses of Chamber-Specific Human iPSC-Derived Cardiomyocytes for In Vitro Cardiotoxicity Studies

Loading PDF document…

Download Differential Responses of Chamber-Specific Human iPSC-Derived Cardiomyocytes for In Vitro Cardiotoxicity Studies PDF

Enter your details to unlock PDF access and receive your download link.

More information

The poster titled Differential Responses of Chamber-Specific Human iPSC-Derived Cardiomyocytes for In Vitro Cardiotoxicity Studies presents Axol Bioscience’s advanced platform for cardiac safety screening using human iPSC-derived cardiomyocytes with defined chamber identities.

Key highlights include:

  • axoCells™ Atrial & Ventricular Cardiomyocytes: Derived from the same donor, validated by MLC2A/MLC2V expression and TempO-Seq transcriptomics. Atrial cells express KCNA5, NPPA, SLN; ventricular cells express HEY2, MYH7, MYL2.
  • Left Ventricular Cardiomyocytes: A novel differentiation protocol yields ~90% purity with complete loss of atrial markers and ventricular-like action potentials.
  • FLEXcyte™ 96 Contractility Assay: Measures beat rate, force amplitude, and beat-width. Atrial cells show faster beat rate and lower force; ventricular cells show stronger contraction.
  • Drug Responses:
    • Carbachol: Atrial-specific response due to I_KACh current.
    • S-Bay K8644 (Ca²⁺ agonist): Opposing effects—atrial cells show reduced beat rate and increased force; ventricular cells show increased beat rate and reduced force.
  • MyoMax™ Maturation Media: Promotes adult-like cardiomyocyte features including:
    • Rod-shaped morphology and sarcomere alignment
    • Shorter field potential duration (FPD)
    • Faster conduction velocity
    • Upregulated fatty acid metabolism genes (MDH1, ACAT1, FABP3)
  • Electrophysiological Profiling: MEA analysis confirms improved maturity and functional performance in MyoMax-treated cells.

This platform enables chamber-specific cardiotoxicity screening with enhanced physiological relevance and supports drug development pipelines targeting cardiac safety.

Featured Axol Products:

  • axoCells™ Atrial Cardiomyocytes – ax0510
  • axoCells™ Ventricular Cardiomyocytes – ax0500
  • axoCells™ Left Ventricular Cardiomyocytes – ax0505
  • MyoMax™ Maturation Media – ax8001
  • axoCells™ Cardiomyocyte Maintenance Media – ax8000